Morgan Stanley
ADCT icon

Morgan Stanley’s ADC Therapeutics ADCT Stock Holding History

Morgan Stanley’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Sell
3,051,173
-761,409
-20% -$2.22M ﹤0.01% 4532
2026
Q1 		$14.3M Buy
3,812,582
+42,839
+1% +$169K ﹤0.01% 3259
2025
Q4 		$13.3M Buy
3,769,743
+100,676
+3% +$409K ﹤0.01% 3343
2025
Q3 		$14.7M Buy
3,669,067
+623,494
+20% +$1.97M ﹤0.01% 3191
2025
Q2 		$8.16M Buy
3,045,573
+25,988
+0.9% +$54.7K ﹤0.01% 3626
2025
Q1 		$4.26M Sell
3,019,585
-936,587
-24% -$1.59M ﹤0.01% 4061
2024
Q4 		$7.87M Buy
3,956,172
+915,378
+30% +$2.4M ﹤0.01% 3603
2024
Q3 		$9.58M Buy
3,040,794
+75,565
+3% +$238K ﹤0.01% 3461
2024
Q2 		$9.37M Buy
2,965,229
+244,834
+9% +$973K ﹤0.01% 3374
2024
Q1 		$12.2M Buy
2,720,395
+1,938,458
+248% +$7.15M ﹤0.01% 3177
2023
Q4 		$1.3M Buy
781,937
+117,910
+18% +$109K ﹤0.01% 4777
2023
Q3 		$596K Buy
664,027
+11,249
+2% +$15K ﹤0.01% 5087
2023
Q2 		$1.4M Buy
652,778
+214,829
+49% +$483K ﹤0.01% 4627
2023
Q1 		$854K Buy
437,949
+87,176
+25% +$322K ﹤0.01% 4944
2022
Q4 		$1.35M Buy
350,773
+67,761
+24% +$271K ﹤0.01% 4697
2022
Q3 		$1.36M Buy
283,012
+77,444
+38% +$561K ﹤0.01% 4677
2022
Q2 		$1.63M Buy
205,568
+119,703
+139% +$1.13M ﹤0.01% 4684
2022
Q1 		$1.26M Buy
85,865
+15,022
+21% +$238K ﹤0.01% 4840
2021
Q4 		$1.43M Sell
70,843
-14,014
-17% -$338K ﹤0.01% 4830
2021
Q3 		$2.3M Sell
84,857
-164,670
-66% -$4.22M ﹤0.01% 4455
2021
Q2 		$6.08M Buy
249,527
+45,300
+22% +$1.05M ﹤0.01% 3583
2021
Q1 		$4.99M Buy
204,227
+94,416
+86% +$2.74M ﹤0.01% 3406
2020
Q4 		$3.52M Buy
109,811
+99,320
+947% +$3.25M ﹤0.01% 3645
2020
Q3 		$346K Sell
10,491
-2,094
-17% -$90.6K ﹤0.01% 4824
2020
Q2 		$589K Buy
+12,585
New +$478K ﹤0.01% 4519

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's ADCT Position: Q2 2026 in Review

Morgan Stanley reduced its ADC Therapeutics (ADCT) stake by 20% in Q2 2026, selling an estimated $2.22M and leaving 3,051,173 shares worth $3.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4532.

Morgan Stanley first reported a position in ADCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $14.7M in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Morgan Stanley held 3,051,173 shares of ADC Therapeutics worth $3.26M as of Q2 2026.
  • Morgan Stanley sold 761,409 ADC Therapeutics shares in Q2 2026, an estimated $2.22M.
  • ADC Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4532 holding.
  • Morgan Stanley first reported a position in ADC Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's ADC Therapeutics position peaked at $14.7M in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.